NEKTAR THERAPEUTICS — Director's Dealing 2023

Dec 16, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2023-12-13

Reporting Person: Wilson Mark Andrew (Chief Legal Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-13	Stock Option	$0.50	A	325000	Acquired	2031-12-12	Common Stock (325000)	Direct

Footnotes

F1: This stock option vests over three years from the date of grant, (December 13, 2023) in equal monthly installments based on continued service.